Improving surveillance for Barrett's oesophagus: AspECT and BOSS trials provide an evidence base [11]

British Medical Journal

Volumn 332, Issue 7556, 2006, Pages 1512-

  Jankowski, Janusz ^a   Barr, Hugh ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b GLOUCESTERSHIRE ROYAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ESOMEPRAZOLE;

ANXIETY; BARRETT ESOPHAGUS; CANCER GROWTH; CANCER INCIDENCE; CHEMOPROPHYLAXIS; CLINICAL PROTOCOL; CLINICAL TRIAL; EVIDENCE BASED MEDICINE; GASTROINTESTINAL ENDOSCOPY; GASTROINTESTINAL REFLUX; HEALTH PROGRAM; HEALTH SURVEY; HUMAN; INFORMED CONSENT; LETTER; MORBIDITY; MORTALITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; TOTAL QUALITY MANAGEMENT; TREATMENT OUTCOME; MASS SCREENING; METHODOLOGY; NOTE;

BARRETT ESOPHAGUS; CLINICAL TRIALS; HUMANS; MASS SCREENING;

EID: 33745685183     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (3)

1. Bampton PA, Schloithe A, Bull J, Fraser RJ, Padbury RTA, Watson DI. Improving surveillance for Barrett's oesophagus. BMJ 2005;332:1390-3. (3 June.)
2. Jankowski J, Hawk E. A methodological analysis of chemoprevention in the Gastrointestinal tract. Nature Clin Pract Gastro 2006;3:101-11.
3. Jankowski J, Moayyedi P. Aspirin as chemoprevention for Barrett's esophagus: a large RCT underway in the UK. (extended original research correspondence). J Natl Cancer Inst 2004;96:885-7.